Loading...

DNTH DIANTHUS THERAPEUTICS INC Company Mergers 8-K Filing

DNTH

DNTH

DIANTHUS THERAPEUTICS INC

(DNTH)

2025 8-K

Financial Results Report

FDA Approval Updates

Stock Offering Agreement

Financial Results Update

Financial Update

Financial Results Announcement

Corporate Update

License Agreement Signed

Funding Agreement

Positive Trial Results

Financial Statements

Financial Statements

Financial Results

Corporate Update

Financial Results

Management Appointment

Earnings Reports

Annual Meeting of Stockholders

Earnings Reports

Earnings Reports

Private Placement

Financial Results Disclosure

Reverse Stock Split and Rev...

Earnings Reports

Appointment of New Independ...

Merger and Name Change

Departure of Directors or C...

Merger Agreement

Termination of Sublease Agr...

Stockholder Rights Plan

Financial Condition and Res...

Delisting Notice

External Links:

On October 16, 2025, Dianthus Therapeutics, Inc. entered a significant License Agreement with Nanjing Leads Biolabs for exclusive rights to develop DNTH212 globally outside Greater China, with potential payments totaling $1 billion; the company had approximately $555 million in cash as of September 30, 2025.

AI Assistant

DIANTHUS THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.